157 related articles for article (PubMed ID: 18571549)
1. Permanent neonatal diabetes mellitus caused by a novel homozygous (T168A) glucokinase (GCK) mutation: initial response to oral sulphonylurea therapy.
Turkkahraman D; Bircan I; Tribble ND; Akçurin S; Ellard S; Gloyn AL
J Pediatr; 2008 Jul; 153(1):122-6. PubMed ID: 18571549
[TBL] [Abstract][Full Text] [Related]
2. Four novel cases of permanent neonatal diabetes mellitus caused by homozygous mutations in the glucokinase gene.
Bennett K; James C; Mutair A; Al-Shaikh H; Sinani A; Hussain K
Pediatr Diabetes; 2011 May; 12(3 Pt 1):192-6. PubMed ID: 21518409
[TBL] [Abstract][Full Text] [Related]
3. Glucokinase (GCK) mutations in hyper- and hypoglycemia: maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemia of infancy.
Gloyn AL
Hum Mutat; 2003 Nov; 22(5):353-62. PubMed ID: 14517946
[TBL] [Abstract][Full Text] [Related]
4. KCNJ11 activating mutations in Italian patients with permanent neonatal diabetes.
Massa O; Iafusco D; D'Amato E; Gloyn AL; Hattersley AT; Pasquino B; Tonini G; Dammacco F; Zanette G; Meschi F; Porzio O; Bottazzo G; Crinó A; Lorini R; Cerutti F; Vanelli M; Barbetti F;
Hum Mutat; 2005 Jan; 25(1):22-7. PubMed ID: 15580558
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneity in disease severity in a family with a novel G68V GCK activating mutation causing persistent hyperinsulinaemic hypoglycaemia of infancy.
Wabitsch M; Lahr G; Van de Bunt M; Marchant C; Lindner M; von Puttkamer J; Fenneberg A; Debatin KM; Klein R; Ellard S; Clark A; Gloyn AL
Diabet Med; 2007 Dec; 24(12):1393-9. PubMed ID: 17976205
[TBL] [Abstract][Full Text] [Related]
6. [Low doses of sulphonyluria as a successful replacement for insulin therapy in a patient with neonatal diabetes due to a mutation of KCNJ11 gene encoding Kir6.2].
Ille J; Putarek NR; Radica A; Hattersley A; Ellard S; Dumić M
Lijec Vjesn; 2010; 132(3-4):90-3. PubMed ID: 20540435
[TBL] [Abstract][Full Text] [Related]
7. Permanent neonatal diabetes caused by a homozygous nonsense mutation in the glucokinase gene.
Rubio-Cabezas O; Díaz González F; Aragonés A; Argente J; Campos-Barros A
Pediatr Diabetes; 2008 Jun; 9(3 Pt 1):245-9. PubMed ID: 18298419
[TBL] [Abstract][Full Text] [Related]
8. Outpatient transition of an infant with permanent neonatal diabetes due to a KCNJ11 activating mutation from subcutaneous insulin to oral glyburide.
Bremer AA; Ranadive S; Lustig RH
Pediatr Diabetes; 2008 Jun; 9(3 Pt 1):236-9. PubMed ID: 18221420
[TBL] [Abstract][Full Text] [Related]
9. A report of 2 new cases of MODY2 and review of the literature: implications in the search for type 2 diabetes drugs.
Shammas C; Neocleous V; Phelan MM; Lian LY; Skordis N; Phylactou LA
Metabolism; 2013 Nov; 62(11):1535-42. PubMed ID: 23890519
[TBL] [Abstract][Full Text] [Related]
10. A novel glucokinase gene mutation and its effect on glycemic/C-peptide fluctuations in a patient with maturity-onset diabetes of the young type 2.
Loomba-Albrecht LA; Jame M; Bremer AA
Diabetes Res Clin Pract; 2010 Mar; 87(3):e23-5. PubMed ID: 20015564
[TBL] [Abstract][Full Text] [Related]
11. New uses for old drugs: neonatal diabetes and sulphonylureas.
Ashcroft FM
Cell Metab; 2010 Mar; 11(3):179-81. PubMed ID: 20197050
[TBL] [Abstract][Full Text] [Related]
12. Variability in the age at diagnosis of diabetes in two unrelated patients with a homozygous glucokinase gene mutation.
Durmaz E; Flanagan S; Berdeli A; Semiz S; Akcurin S; Ellard S; Bircan I
J Pediatr Endocrinol Metab; 2012; 25(7-8):805-8. PubMed ID: 23155716
[TBL] [Abstract][Full Text] [Related]
13. An oral sulfonylurea in the treatment of transient neonatal diabetes mellitus.
Loomba-Albrecht LA; Glaser NS; Styne DM; Bremer AA
Clin Ther; 2009 Apr; 31(4):816-20. PubMed ID: 19446154
[TBL] [Abstract][Full Text] [Related]
14. Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11.
Mlynarski W; Tarasov AI; Gach A; Girard CA; Pietrzak I; Zubcevic L; Kusmierek J; Klupa T; Malecki MT; Ashcroft FM
Nat Clin Pract Neurol; 2007 Nov; 3(11):640-5. PubMed ID: 17982434
[TBL] [Abstract][Full Text] [Related]
15. Diabetic retinopathy in permanent neonatal diabetes due to Kir6.2 gene mutations: the results of a minimum 2-year follow-up after the transfer from insulin to sulphonylurea.
Klupa T; Skupien J; Mirkiewicz-Sieradzka B; Gach A; Noczynska A; Szalecki M; Kozek E; Sieradzki J; Mlynarski W; Malecki MT
Diabet Med; 2009 Jun; 26(6):663-4. PubMed ID: 19538247
[No Abstract] [Full Text] [Related]
16. [Neonatal diabetes mellitus].
Huopio H; Otonkoski T
Duodecim; 2011; 127(6):534-41. PubMed ID: 21528518
[TBL] [Abstract][Full Text] [Related]
17. Phenotypic severity of homozygous GCK mutations causing neonatal or childhood-onset diabetes is primarily mediated through effects on protein stability.
Raimondo A; Chakera AJ; Thomsen SK; Colclough K; Barrett A; De Franco E; Chatelas A; Demirbilek H; Akcay T; Alawneh H; ; Flanagan SE; Van De Bunt M; Hattersley AT; Gloyn AL; Ellard S;
Hum Mol Genet; 2014 Dec; 23(24):6432-40. PubMed ID: 25015100
[TBL] [Abstract][Full Text] [Related]
18. Transfer to sulphonylurea therapy in adult subjects with permanent neonatal diabetes due to KCNJ11-activating [corrected] mutations: evidence for improvement in insulin sensitivity.
Malecki MT; Skupien J; Klupa T; Wanic K; Mlynarski W; Gach A; Solecka I; Sieradzki J
Diabetes Care; 2007 Jan; 30(1):147-9. PubMed ID: 17192350
[No Abstract] [Full Text] [Related]
19. Sulphonylurea therapy improves cognition in a patient with the V59M KCNJ11 mutation.
Slingerland AS; Hurkx W; Noordam K; Flanagan SE; Jukema JW; Meiners LC; Bruining GJ; Hattersley AT; Hadders-Algra M
Diabet Med; 2008 Mar; 25(3):277-81. PubMed ID: 18307455
[TBL] [Abstract][Full Text] [Related]
20. Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2.
Zung A; Glaser B; Nimri R; Zadik Z
J Clin Endocrinol Metab; 2004 Nov; 89(11):5504-7. PubMed ID: 15531505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
